(Q35868420)

10 August 2017

1 reference

title

Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease (English)

1 reference

10 August 2017

1 reference

1 reference

Dirk Deleu

1

1 reference

10 August 2017

Yolande Hanssens

series ordinal

2

1 reference

10 August 2017

Margaret G Northway

series ordinal

3

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

21

1 reference

10 August 2017

11

1 reference

10 August 2017

687-709

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200421110-00001

10 August 2017

0 references

cites work

Clinicopathological study of 35 cases of multiple system atrophy.

1 reference

12 December 2020

1 reference

12 December 2020

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

1 reference

12 December 2020

Apomorphine in the treatment of Parkinson's disease

1 reference

12 December 2020

Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years

1 reference

12 December 2020

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

1 reference

12 December 2020

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

1 reference

12 December 2020

Mood changes associated with "end-of-dose deterioration" in Parkinson's disease: a controlled study

1 reference

12 December 2020

Dopamine receptors in the basal ganglia: relevance to Parkinson's disease

1 reference

12 December 2020

Motor response to repeated dopaminergic stimulation in Parkinson's disease

1 reference

12 December 2020

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

1 reference

12 December 2020

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

1 reference

12 December 2020

Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

1 reference

12 December 2020

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor

1 reference

12 December 2020

Role of subcutaneous apomorphine in parkinsonian voiding dysfunction

1 reference

12 December 2020

Apomorphine test in de novo Parkinson's disease

1 reference

12 December 2020

Apomorphine infusional therapy in Parkinson's disease: clinical utility and lack of tolerance

1 reference

12 December 2020

Response of parkinsonian swallowing dysfunction to dopaminergic stimulation

1 reference

12 December 2020

Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.

1 reference

12 December 2020

GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine

1 reference

12 December 2020

Panniculitis in association with apomorphine infusion

1 reference

12 December 2020

Severe oedema after subcutaneous apomorphine in Parkinson's disease

1 reference

12 December 2020

Sleep attacks with apomorphine

1 reference

12 December 2020

The short-duration response to apomorphine: implications for the mechanism of dopaminergic effects in parkinsonism.

1 reference

12 December 2020

Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys

1 reference

12 December 2020

Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT

1 reference

12 December 2020

Current status of dopamine agonists in Parkinson's disease management

1 reference

12 December 2020

Apomorphine and lisuride infusion. A comparative chronic study

1 reference

12 December 2020

Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease.

1 reference

12 December 2020

Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.

1 reference

12 December 2020

Neuroprotection by dopamine agonists.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events

1 reference

12 December 2020

Does an inhibitory action of levodopa contribute to motor fluctuations?

1 reference

12 December 2020

Apomorphine in Parkinson's disease

1 reference

12 December 2020

Time course of tolerance to apomorphine in parkinsonism

1 reference

12 December 2020

Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon?

1 reference

12 December 2020

Anal sphincter dysfunction in Parkinson's disease

1 reference

12 December 2020

Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study

1 reference

12 December 2020

Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease

1 reference

12 December 2020

Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine

1 reference

12 December 2020

Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients

1 reference

12 December 2020

1 reference

12 December 2020

Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction.

1 reference

12 December 2020

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

12 December 2020

Apomorphine in patients with Parkinson's disease.

1 reference

12 December 2020

Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease

1 reference

12 December 2020

The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.

1 reference

12 December 2020

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

12 December 2020

Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study

1 reference

12 December 2020

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

1 reference

12 December 2020

Dose response and concentration response relationship of apomorphine in patients with Parkinson's disease and end-of-dose akinesia

1 reference

12 December 2020

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients

1 reference

12 December 2020

Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans

1 reference

12 December 2020

Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses

1 reference

12 December 2020

Pharmacokinetics of apomorphine in parkinsonian patients

1 reference

12 December 2020

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

1 reference

12 December 2020

Comparison of motor response to apomorphine and levodopa in Parkinson's disease

1 reference

12 December 2020

Challenge tests to predict the dopaminergic response in untreated Parkinson's disease

1 reference

12 December 2020

FDA committee recommends approval for viagra rival

1 reference

12 December 2020

Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease

1 reference

12 December 2020

[Treatment of motor fluctuations in Parkinson's disease with subcutaneous injections of apomorphine]

1 reference

12 December 2020

Transient atrial fibrillation after subcutaneous apomorphine bolus.

1 reference

12 December 2020

Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans

1 reference

12 December 2020

1 reference

12 December 2020

Peripheral pharmacokinetics of apomorphine in humans

1 reference

12 December 2020

Apomorphine test in the assessment of parkinsonian patients: a meta-analysis

1 reference

12 December 2020

Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease

1 reference

12 December 2020

The motor response to repeated apomorphine administration in Parkinson's disease

1 reference

12 December 2020

Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.

1 reference

12 December 2020

Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes

1 reference

12 December 2020

The motor response to sequential apomorphine in parkinsonian fluctuations

1 reference

12 December 2020

Apomorphine SC treatment in parkinsonian patients with long-term L-dopa syndrome during L-dopa drug holiday

1 reference

12 December 2020

Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine

1 reference

12 December 2020

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes

1 reference

12 December 2020

Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.

1 reference

12 December 2020

Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations

1 reference

12 December 2020

Treatment of Parkinson's disease with aporphines. Possible role of growth hormone

1 reference

12 December 2020

Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine

1 reference

12 December 2020

Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis.

1 reference

12 December 2020

Use of apomorphine in clinical practice

1 reference

12 December 2020

Diurnal responsiveness to apomorphine

1 reference

12 December 2020

Apomorphine hyperpigmentation

1 reference

12 December 2020

The dopaminergic response in multiple system atrophy

1 reference

12 December 2020

Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.

1 reference

12 December 2020

Apomorphine tolerance in Parkinson's disease: lack of a dose effect.

1 reference

12 December 2020

Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment

1 reference

12 December 2020

Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application

1 reference

12 December 2020

On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

1 reference

12 December 2020

Concentration-effect relationship of levodopa in patients with Parkinson's disease

1 reference

12 December 2020

The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: a histologic study

1 reference

12 December 2020

Motor response following repeated apomorphine administration is reduced in Parkinson's disease

1 reference

12 December 2020

Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up

1 reference

12 December 2020

Long-term treatment with intermitent intranasal or subcutaneous apormorphine in patients with levodopa-related motor fluctuations

1 reference

12 December 2020

Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results

1 reference

12 December 2020

Apomorphine protects against MPTP-induced neurotoxicity in mice.

1 reference

12 December 2020

Pathophysiology of L-dopa-induced dyskinesias.

1 reference

12 December 2020

Apomorphine in the diagnosis and treatment of parkinsonian tremor.

1 reference

12 December 2020

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity

1 reference

12 December 2020

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

12 December 2020

Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.

1 reference

12 December 2020

Apomorphine test for dopaminergic responsiveness: a dose assessment study

1 reference

12 December 2020

Subcutaneous apomorphine as a diagnostic test for dopaminergic responsiveness in parkinsonian syndromes

1 reference

12 December 2020

Subcutaneous apomorphine in the treatment of Parkinson's disease

1 reference

12 December 2020

Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease

1 reference

12 December 2020

SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS

1 reference

12 December 2020

Sleep attacks in patients taking dopamine agonists: review

1 reference

12 December 2020

Acute challenge with apomorphine and levodopa in Parkinsonism

1 reference

12 December 2020

A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease

1 reference

12 December 2020

Dopamine agonists in Parkinson's disease: a look at apomorphine

1 reference

12 December 2020

Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model

1 reference

12 December 2020

The effect of apomorphine administration on smooth pursuit ocular movements in early Parkinsonian patients

1 reference

12 December 2020

Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats.

1 reference

12 December 2020

The apomorphine test in parkinsonian syndromes

1 reference

12 December 2020

Painful Parkinson's disease

1 reference

12 December 2020

Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes

1 reference

12 December 2020

Injected apomorphine and orally administered levodopa in Parkinsonism

1 reference

12 December 2020

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

1 reference

12 December 2020

10.2165/00002512-200421110-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1025080318

0 references

Fatcat ID

release_r2u4sudzujeblgljq2i7egafiy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r2u4sudzujeblgljq2i7egafiy

24 November 2022

mapped directly with Wikidata item

1 reference